Cediranib
Cediranib (AZD2171) is a highly potent, orally available VEGFR tyrosine kinase inhibitor with IC50s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively.
Product Specifications
CAS Number
[288383-20-0]
Product Name Alternative
AZD2171
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Autophagy; PDGFR; VEGFR
Type
Reference compound
Related Pathways
Autophagy; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Cediranib.html
Purity
99.87
Solubility
DMSO : 20 mg/mL (ultrasonic)
Smiles
FC1=C(OC2=C(C(C=C3OCCCN4CCCC4)=NC=N2)C=C3OC)C=CC5=C1C=C(C)N5
Molecular Formula
C25H27FN4O3
Molecular Weight
450.51
Precautions
H302, H315, H319, H335
References & Citations
[1]Wedge SR, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res, 2005, 65 (10), 4389-4400.|[2]Zhang L, et al. Pleiotrophin promotes vascular abnormalization in gliomas and correlates with poor survival in patients with astrocytomas. Sci Signal. 2015 Dec 8;8 (406) :ra125.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
PDGFRα; PDGFRβ; VEGFR1/Flt-1; VEGFR2/KDR/Flk-1; VEGFR3/Flt-4
Citation 01
Biomaterials. 2018 Apr;161:164-178. |Biomed Res Int. 2021 Mar 29:2021:5582648.|Cell Stem Cell. 2019 Sep 5;25 (3) :373-387.e9.|Discov Oncol. 2024 Nov 19;15 (1) :678.|Eur J Pharmacol. 2024 Feb 5:964:176278.|Harvard Medical School LINCS LIBRARY|J Med Chem. 2023 Dec 28;66 (24) :16597-16614.|Neuro Oncol. 2016 Apr;18 (4) :538-48. |Sci Signal. 2015 Dec 8;8 (406) :ra125. |Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.|Life Sci. 2024 Jun 23:122862.
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
